SCHEMBL5046512

SCHEMBL5046512

Cc1ccc(NC=O)cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAPGEF4 Q8WZA2 1/20 0.50
ALDH1A1 P00352 6/20 0.48
MAPT P10636 4/20 0.48
KMT2A Q03164 2/20 0.48
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48
POLB P06746 1/20 0.48
SMN1; SMN2 Q16637 5/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
HPGD P15428 3/20 0.46
HTT P42858 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
FKBP1A P62942 1/20 0.45
TP53 P04637 1/20 0.44
THRB P10828 1/20 0.44
AGTR1 P30556 2/20 0.44
GAA P10253 2/20 0.44
RECQL P46063 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formamide SCHEMBL10553563 0.94 MAPT (0.46) RAPGEF4ALDH1A1MAPTKMT2AKDM4E
SCHEMBL2094001 0.84 NPC1 (0.41) RAPGEF4ALDH1A1MAPTKMT2AKDM4E
SCHEMBL30555452 0.81 MAPT (0.49) ALDH1A1MAPTKMT2AMEN1POLB
SCHEMBL5543216 0.81 MAPT (0.49) ALDH1A1MAPTKMT2AMEN1POLB
SCHEMBL244815 0.81 EPHX1 (0.52) ALDH1A1MAPTKMT2AKDM4EMEN1
SCHEMBL6666096 0.80 MAPT (0.50) RAPGEF4ALDH1A1MAPTKMT2AMEN1
SCHEMBL9597648 0.78 ALDH1A1 (0.41) ALDH1A1MAPTKMT2AMEN1POLB
SCHEMBL28009999 0.76 ALDH1A1 (0.49) ALDH1A1MAPTKMT2AMEN1SMN1; SMN2
SCHEMBL2324287 0.76 KMT2A (0.46) ALDH1A1MAPTKMT2AMEN1POLB
SCHEMBL28010592 0.76 NPC1 (0.53) ALDH1A1MAPTKMT2AKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1912634-A2 PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY Bayer Healthcare, LLC (US) 2008-04-23 EP claimed
WO-2007016538-A2 PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY BAYER HEALTHCARE LLC (US) 2007-02-08 WO claimed
EP-1189891-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION Bioscience AG (DE) 2002-03-27 EP claimed
US-6362342-B1 BIOSYNTHESIS; DRUG LIBRARIES LION BIOSCIENCE AG (DE) 2002-03-26 US claimed
WO-2001000594-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2001-01-04 WO claimed
WO-2021047674-A1 BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR 南京明德新药研发有限公司 2021-03-18 WO disclosed
US-20170342089-A1 NOVEL COMPOUNDS AS MODULATORS OF GPR-119 RHIZEN PHARMACEUTICALS SA (CH) 2017-11-30 US disclosed
US-9777018-B2 Compounds as modulators of GPR-119 RHIZEN PHARMACEUTICALS SA (CH) 2017-10-03 US disclosed
EP-2585064-B1 C5AR ANTAGONISTS CHEMOCENTRYX INC (US) 2017-05-03 EP disclosed
US-20150361092-A1 NOVEL COMPOUNDS AS MODULATORS OF GPR-119 RHIZEN PHARMACEUTICALS SA (CH) 2015-12-17 US disclosed
US-9181214-B2 Bicyclic compounds as modulators of GPR-119 RHIZEN PHARMACEUTICALS SA (CH) 2015-11-10 US disclosed
EP-1189891-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION Bioscience AG (DE) 2002-03-27 EP disclosed
US-6362342-B1 BIOSYNTHESIS; DRUG LIBRARIES LION BIOSCIENCE AG (DE) 2002-03-26 US disclosed
WO-2001000594-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2001-01-04 WO disclosed
US-4595781-A N,N'-dithiobisformanilides and their use in diene rubber MONSANTO COMPANY (US) 1986-06-17 US disclosed
US-4391953-A Diene rubber compositions containing N,N'-dithioformanilide crosslinkers MONSANTO COMPANY (US) 1983-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150361092-A1 NOVEL COMPOUNDS AS MODULATORS OF GPR-119 GPR119, GPR39, GPBAR1 RAPGEF4 415/4885ALDH1A1 2322/4885MAPT 3977/4885
US-20170342089-A1 NOVEL COMPOUNDS AS MODULATORS OF GPR-119 GPR119, GPR39, GPBAR1 RAPGEF4 415/4885ALDH1A1 2322/4885MAPT 3977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.